Menu
Not yet recruiting NCT07380893

Left Ventricular Hypertrophy in CKD Patients

— Observational Left Ventricular Hypertrophy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: transthoracic echocardiography.
Who it may be relevant to
Registry conditions: Left Ventricular Hypertrophy. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy

Overview

The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients. The main question it aims to answer is: Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?

Detailed description

The prevalence of LVH in CKD patients has been reported to range from 40% to 75%, depending on disease stage, blood pressure control, and diagnostic methodology. LVH typically develops early and worsens with CKD progression, reflecting the close interplay between renal dysfunction and cardiac remodeling.

Anemia is a prominent non-hemodynamic contributor to LVH in CKD. Reduced erythropoietin (EPO) production by the damaged kidneys, together with iron deficiency and chronic inflammation, leads to decreased oxygen delivery, compensatory cardiac output elevation, and subsequent ventricular hypertrophy.

Given the strong association between CKD, anemia, and cardiovascular remodeling, investigating the prevalence of LVH and the effect of erythropoietin therapy on left ventricular mass among CKD patients can provide critical insights into optimizing cardiovascular risk management in this high-risk group.

this study will be conducted to :

1. To determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital. 2. To assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.

A total of 100 CKD patients will be included.

* Phase I : All CKD patients will undergo echocardiographic evaluation to determine the prevalence of LVH. * Phase II : Among anemic CKD patients with LVH receiving erythropoietin therapy , will be followed for 6 months

Interventions

  • Radiation transthoracic echocardiography
    Standard transthoracic echocardiography will be performed for all participants, measuring: * Left ventricular end-diastolic diameter (LVEDD) * Interventricular septal thickness (IVSD) * Posterior wall thickness (PWD) * Left ventricular mass (LVM) * Left ventricular mass index (LVMI = LVM/body surface area)

Primary outcome measures

  • Change in LVMI following erythropoietin therapy in anemic CKD patients. [Time frame: - baseline transthoracic echocardiography will be performed for all group study.]
Secondary outcome measures (1)
  • Association between hemoglobin level and LVMI. [Time frame: 6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.]

Eligibility criteria

Inclusion criteria

  • Adults (≥18 years) diagnosed with CKD stages 3-5.
  • Stable clinical condition for ≥3 months.
  • Anemia (Hb <10 g/dL) for cohort phase.
  • Willingness to participate and provide informed consent.

Exclusion criteria

  • Valvular or ischemic heart disease.
  • Uncontrolled hypertension (BP >180/110 mmHg).
  • Acute coronary syndrome or decompensated heart failure in the past 3 months.
  • Malignancy or active infection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07380893 · Soh-Med--25-11-7MS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗